NGS-Based RNA Sequencing Market Size and Growth
The NGS-Based RNA Sequencing Market size reached USD 4.4 billion in 2025 and is estimated to reach USD 29.95 billion by 2035, growing at a CAGR of 19% during the forecast period (2026-2035). NGS-Based RNA-Sequencing is a technology used in identifying and determining the order of nucleotides in an RNA sequence.
This technique plays a vital role in analyzing transcriptomics and gene expression. NGS-Based RNA-Sequencing is a faster and more reliable technology to obtain genetic information from samples, and at a lower cost than ever before with a significant increase in throughput capabilities.
Key Takeaways
- Commercial demand continues to expand as RNA sequencing moves beyond academic research into routine clinical diagnostics and precision medicine.
- The market is projected to approach USD 30 billion by 2035, reflecting sustained investments across healthcare, pharmaceutical research, and biotechnology.
- RNA sequencing platforms and consumables remain the leading revenue-generating segment due to recurring reagent purchases and continuous technology upgrades.
- North America maintains leadership through established genomic infrastructure, extensive funding programs, and the presence of leading sequencing technology providers.
- Asia Pacific is expected to record the fastest expansion as governments strengthen genomic medicine programs and biotechnology manufacturing capabilities.
- AI-driven RNA sequencing analytics are reducing interpretation time, improving scalability, and increasing adoption among hospitals and diagnostic laboratories.
- Vendors offering integrated sequencing platforms, consumables, bioinformatics software, and technical support are likely to strengthen competitive positioning throughout the forecast period.
Market Scope
| Metrics | Details |
| Market Size (2025) | USD 4.40 Billion |
| Forecast Market Size (2035) | USD 29.95 Billion |
| CAGR (2026-2035) | 19% |
| Historic Years | 2023-2024 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Segments Covered | Product & Services, Technology, Application, End User, and Region |
| Largest Regional Market | North America |
| Fastest Growing Region | Asia Pacific |
To Know More Insights: Download Sample
Market Dynamics and Trends
The global NGS based RNA Sequencing Market growth is driven by the surge in the number of product approvals for RNA-sequencing platforms and consumables, advancements in data analysis & storage, automation in sample generation techniques, as well as augmenting genomic research in the fields of rare genetic diseases and autoimmune diseases are leading to growth in adoption of NGS-based RNA-Sequencing products.
Advantages of RNA-sequencing over the conventional technologies is expected to drive the growth in the forecast period
NGS-based RNA-sequencing offers several advantages over the conventional methods for transcriptome analysis with cost-effective procedures. Since it allows direct quantification and identification of transcripts, it is becoming a de facto standard approach for investigating and optimizing mammalian cells. In addition, NGS-based RNA-sequencing eliminates non-ideal hybridization and cross-hybridization, as observed in microarrays. This technique provides absolute values with higher specificity and can quantify the large dynamic range of expression levels. Since NGS-based RNA-sequencing allows the detection of novel transcripts, this technology is emerging as an alternative to whole-genome transcriptome profiling. Therefore, as mentioned above, these factors are collectively responsible for the growth of the NGS based RNA Sequencing Market over the analysis period.
Instability of RNA under normal conditions are likely to hinder the market growth
The instability of RNA under normal conditions and lack of standardization are expected to hinder the market growth in the coming years.
Segmentation Analysis
The market is segmented by Product & Services (RNA Sequencing Platforms & Consumables, Services), by Technology, by Application, by End User, and by Region, Share, Trends, and Forecast to 2035.
RNA sequencing platforms and consumables continue to represent the largest revenue-generating category. Continuous product innovation from major sequencing technology providers has expanded laboratory capabilities while supporting recurring revenue through consumable sales. Advanced sequencing systems enable accurate detection of transcript isoforms, gene fusions, single nucleotide variants, and differential gene expression, making them indispensable across biomedical research and clinical applications.
Applications continue to diversify across oncology, autoimmune disorders, rare genetic diseases, infectious disease surveillance, and translational medicine. Increasing demand for comprehensive molecular characterization is expected to support sustained adoption throughout the forecast period.
End users increasingly include pharmaceutical companies, biotechnology organizations, academic institutions, contract research organizations, clinical laboratories, and hospitals implementing precision medicine initiatives.
Regional Analysis
North America
North America continues to account for the largest share of the global market due to its mature genomic research ecosystem, early adoption of sequencing technologies, and strong presence of leading biotechnology companies. Extensive public and private investments support ongoing research into cancer biology, autoimmune disorders, rare diseases, and precision medicine. The United States remains the primary revenue contributor, supported by advanced healthcare infrastructure, government funding programs, and widespread implementation of RNA sequencing across research institutions and clinical laboratories.
Europe
European countries continue expanding investments in genomic medicine, translational research, and precision healthcare initiatives. Strong collaboration among academic institutions, biotechnology companies, and healthcare providers supports continued adoption of transcriptomic analysis across oncology, molecular diagnostics, and pharmaceutical development. Regulatory emphasis on personalized medicine also contributes to sustained market expansion.
Asia Pacific
Asia Pacific is projected to experience the fastest growth through 2035. Rapid expansion of biotechnology industries, increasing healthcare expenditure, growing genomic research programs, and government support for precision medicine initiatives are accelerating RNA sequencing adoption throughout the region. Expanding pharmaceutical manufacturing capabilities and increasing availability of sequencing infrastructure further strengthen long-term market prospects.
Recent Developments
April 2026: Strategic collaborations for multi-omics integration
Leading genomics firms entered partnerships with healthcare and pharma companies to integrate RNA sequencing with proteomics and genomics platforms, enabling comprehensive multi-omics analysis for drug discovery and disease mechanism studies.
March 2026: Rising adoption in clinical diagnostics and precision medicine
Hospitals and diagnostic labs expanded the use of NGS-based RNA sequencing for clinical applications, particularly in infectious disease profiling and personalized oncology treatment selection. This reflects a shift from research-only usage toward routine clinical deployment.
February 2026: AI-integrated RNA sequencing data analysis tools launched
Bioinformatics companies introduced AI-powered RNA-seq analysis platforms that automate differential gene expression, splice variant detection, and biomarker discovery. This development is reducing turnaround time and improving accuracy in clinical research pipelines.
January 2026: Expansion of single-cell RNA sequencing platforms
Major sequencing solution providers accelerated the rollout of next-generation single-cell RNA-seq workflows, improving resolution for immune profiling and oncology research. This trend is driven by increasing demand for high-precision transcriptomic mapping in cancer and rare disease studies.
Market Companies and Competitive Landscape
The global NGS based RNA Sequencing Market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Illumina, Inc., Oxford Nanopore Technologies, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., PerkinElmer, Inc., F. Hoffmann-La Roche Ltd, Hamilton Company, and Takara Bio Inc. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market. For instance, In May 2021, Bio-Rad Laboratories, Inc. launched SEQuoia RiboDepletion Kit for NGS that eliminates irrelevant ribosomal RNA from the RNA-sequencing library and improves assay efficiency.
NGS based RNA Sequencing Market – Key Companies to Watch
Agilent Technologies, Inc
Overview: Agilent Technologies Inc is a global leader in life sciences, diagnostics and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions and people provide trusted answers to customers' most challenging questions. The company generated revenues of $4.91 billion in fiscal 2018 and employs 15,550 people worldwide.
Product Portfolio: It includes product like SureSelect Strand-Specific RNA Library Preparation kit prepares Poly(A) enriched libraries for whole-transcriptome sequencing. Sequence a wide range of RNA to detect gene expression changes and alternative splicing. The kit contains mRNA sequencing library preparation and enrichment materials.
